Back to School: How biopharma can reboot drug development. Access exclusive analysis here

SurModics drug delivery, diagnostic news

SurModics said it will restructure its executive leadership and corporate functions and realign its workforce to "better position it for long-term growth." The restructuring will eliminate 7 positions (6%) and reduce headcount to 115. SurModics would not disclose from where the cuts would come. SurModics

Read the full 459 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers